Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Catalyst Bio (CBIO)

Catalyst Bio (CBIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 64,045
  • Shares Outstanding, K 12,016
  • Annual Sales, $ 10 K
  • Annual Income, $ -30,060 K
  • 60-Month Beta 2.14
  • Price/Sales 10,594.11
  • Price/Cash Flow N/A
  • Price/Book 0.68

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -1.19
  • Number of Estimates 1
  • High Estimate -1.19
  • Low Estimate -1.19
  • Prior Year -0.64
  • Growth Rate Est. (year over year) -85.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.52 +17.92%
on 10/02/19
6.55 -18.63%
on 09/16/19
-1.14 (-17.62%)
since 09/13/19
3-Month
4.52 +17.92%
on 10/02/19
8.76 -39.16%
on 08/01/19
-3.05 (-36.40%)
since 07/15/19
52-Week
4.52 +17.92%
on 10/02/19
11.44 -53.43%
on 11/08/18
-4.90 (-47.90%)
since 10/15/18

Most Recent Stories

More News
Company News For Oct 4, 2019

Companies in the news are: STZ, BBBY, PEP, CBIO

STZ : 196.76 (+1.96%)
PEP : 136.33 (-0.81%)
BBBY : 11.98 (-2.52%)
CGC : 20.10 (+6.57%)
CBIO : 5.33 (+0.76%)
Catalyst Biosciences Provides DalcA Phase 2b Trial Update

Catalyst Biosciences, Inc. (NASDAQ: CBIO), today provided an update on enrollment in its Phase 2b study of dalcinonacog alfa (DalcA), a next-generation subcutaneously (SQ) administered Factor IX (FIX)...

CBIO : 5.33 (+0.76%)
22NW: Catalyst Biosciences Needs Change Now

Dear Catalyst Biosciences, Inc. Shareholders:

CBIO : 5.33 (+0.76%)
Catalyst Biosciences Enters Oversold Territory

Catalyst Biosciences, Inc. (CBIO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

CBIO : 5.33 (+0.76%)
22NW: Catalyst Biosciences Needs Change Now

Dear Catalyst Biosciences, Inc. Shareholders:

CBIO : 5.33 (+0.76%)
22NW: Catalyst Biosciences Needs Change Now

Dear Catalyst Biosciences, Inc. Shareholders:

CBIO : 5.33 (+0.76%)
Catalyst Biosciences to Present at the Cantor Global Healthcare Conference

Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst Biosciences, will present a corporate overview at the Cantor 2019...

CBIO : 5.33 (+0.76%)
Catalyst Biosciences to Present at the 2019 ASBMB Symposium on Serine Proteases in Pericellular Proteolysis and Signaling Conference

Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced an oral presentation at the 2019 American Society for Biochemistry and Molecular Biology (ASBMB) Symposium on Serine Proteases in Pericellular...

CBIO : 5.33 (+0.76%)
Catalyst Biosciences Announces Transition of Chief Financial Officer

Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that its chief financial officer, Fletcher Payne, will be stepping down from the Company to pursue another opportunity effective August 30, 2019....

CBIO : 5.33 (+0.76%)
Catalyst Biosciences to Present at the 2019 Hemophilia Drug Development Summit

Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced an oral presentation at the Second Annual 2019 Hemophilia Drug Development (HDD) Summit being held from August 20-22, 2019 in Boston.

CBIO : 5.33 (+0.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade CBIO with:

Business Summary

Catalyst Biosciences, Inc. is a biopharmaceutical company which focused on creating and developing medicines to address serious medical conditions. The Company's hemostasis product candidates include CB 813d/PF-0520602, CB 2679d/ISU 304 and FXa. Anti-Complement Product consists of CB 2782 and Ophthalmic...

See More

Key Turning Points

2nd Resistance Point 5.66
1st Resistance Point 5.50
Last Price 5.33
1st Support Level 5.22
2nd Support Level 5.10

See More

52-Week High 11.44
Fibonacci 61.8% 8.80
Fibonacci 50% 7.98
Fibonacci 38.2% 7.17
Last Price 5.33
52-Week Low 4.52

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar